1.Cognitive Function of Thyroid Papillary Carcinoma Patients Before Radioiodine Therapy.
Hyun Seuk KIM ; Jin Sook CHEON ; Min Su KIM ; Young Sik CHOI ; Byoung Hoon OH
Korean Journal of Psychosomatic Medicine 2013;21(2):132-139
OBJECTIVES: The aims of this study were to know the prevalence of cognitive disorders in patients with thyroid cancer, and identify related variables to them. METHODS: Subjects were consisted of fourty-two patients with thyroid cancer, who were admitted for radioiodine ablative therapy at 6-12 months after total thyroidectomy. The data were obtained from interviews about history and assessments of depression and cognitive function(Korean Version of the Montreal Cognitive Assessment, MoCA-K). RESULTS: 1) Among subjects, those with below 22 of total score of the MoCA-K were twenty-one(50.0%). 2) Upon age, education, Pre-radioiodine therapy thyroid stimulating hormone(TSH), there were statistically significant difference between subgroup with above 23 of the total MoCA-K score and those below 22. 3) The total scores of the MoCA-K in subjects had significant correlation with age, education, comorbidity, Pre-radioiodine therapy TSH, total score of the HDRS-17. CONCLUSIONS: Cognitive disorders were more prevalent among patients with thyroid cancer before radioiodine therapy. Therefore, further study should be needed to clarify the mechanism for the cognitive disorders in thyroid cancer. Furthermore, physicians should pay attention to the cognitive function and prepare preventative measures for cognitive disorder during management of thyroid cancer.
Carcinoma, Papillary*
;
Comorbidity
;
Depression
;
Education
;
Humans
;
Prevalence
;
Thyroid Gland*
;
Thyroid Neoplasms
;
Thyroidectomy
;
Thyrotropin
2.A Case Report of Hypokalemic Periodic Paralysis with Arrhythmia.
Byoung Gue NA ; Dae Su KIM ; Sang Moo JUNG ; Sang Woo OH ; Jae Hong CHOE ; Ji Hyun LEE ; Gi Byoung NAM ; Dong Woon KIM ; Myeong Chan CHO
Korean Circulation Journal 1997;27(9):915-921
The hypokalemic periodic paralysis is characterized by intermittent falccid paralysis of extremities with spontaneous recovery. It is rarely accompanied by cardiac arrhythmia, especially fatal ventricular tachycardia or torsades de pointes. We observed a 29 year old man, who had suffered from intermittent periodic paralysis and fatal ventricular tachyarrhythmia. He had the first episode of muscle weakness in his low grade of elementary school, which lasted for 20 -30 hours. Similar episodes of muscle weakness occurred 1 -7 times per year, especially after carbohydrate rich food. On admission to emergency room, his chief complaints were generalized weakness and chest tightness, serum potassium level was 1.6mEq/l, and four extremities showed Grade 0 motor weakness. His electrocardiography(ECG) showed Atrioventricular dissociation due to sinus tachycardia and accelerated junctional rhythm, intraventricular conduction distrubance. During intravenous potassium administration, ECG showed sustained ventricular tachycardia and cardiovascular collapse occurred. So we carried out resuscitation and cardioversion. After resuscitation, he recovered from cardovascular collapse and ECG showed sinus tachycardia. But during continuous monitoring ECG showed torsades de pointes with cardiovascular collapse. We carried out resuscitation and defibrillation repeatedly. Serum potassium level was 1.7 - 1.8mEq/L at that time. After successful resuscitation, ECG showed sinus rhythm, and his mental status was fully recovered. After he admitted to intensive care unit, paralytic attack and cardiac arrhythmia did not occurred any more. Serum potassium level was maintained between 3.9 -6.1lmEq/L during his hospital days. He was fully recovered but could not take any medications(e.g. acetazolamide, potassium supplying agent and antiarrhythmic drugs) due to severe gastrointestinal disturbances. During the 30 months of postdischarge period, he experienced three mild paralysis attacks, but they were not accompanied by chest tightness, palpitation or syncope.
Acetazolamide
;
Adult
;
Arrhythmias, Cardiac*
;
Electric Countershock
;
Electrocardiography
;
Emergency Service, Hospital
;
Extremities
;
Heart Block
;
Humans
;
Hypokalemia
;
Hypokalemic Periodic Paralysis*
;
Intensive Care Units
;
Muscle Weakness
;
Paralysis
;
Potassium
;
Resuscitation
;
Syncope
;
Tachycardia
;
Tachycardia, Sinus
;
Tachycardia, Ventricular
;
Thorax
;
Torsades de Pointes
3.Vitamin D Inhibits Expression and Activity of Matrix Metalloproteinase in Human Lung Fibroblasts (HFL-1) Cells.
Seo Hwa KIM ; Moon Seong BAEK ; Dong Sik YOON ; Jong Seol PARK ; Byoung Wook YOON ; Byoung Su OH ; Jinkyeong PARK ; Hui Jung KIM
Tuberculosis and Respiratory Diseases 2014;77(2):73-80
BACKGROUND: Low levels of serum vitamin D is associated with several lung diseases. The production and activation of matrix metalloproteinases (MMPs) may play an important role in the pathogenesis of emphysema. The aim of the current study therefore is to investigate if vitamin D modulates the expression and activation of MMP-2 and MMP-9 in human lung fibroblasts (HFL-1) cells. METHODS: HFL-1 cells were cast into three-dimensional collagen gels and stimulated with or without interleukin-1beta (IL-1beta) in the presence or absence of 100 nM 25-hydroxyvitamin D (25(OH)D) or 1,25-dihydroxyvitamin D (1,25(OH)2D) for 48 hours. Trypsin was then added into the culture medium in order to activate MMPs. To investigate the activity of MMP-2 and MMP-9, gelatin zymography was performed. The expression of the tissue inhibitor of metalloproteinase (TIMP-1, TIMP-2) was measured by enzyme-linked immunosorbent assay. Expression of MMP-9 mRNA and TIMP-1, TIMP-2 mRNA was quantified by real time reverse transcription polymerase chain reaction. RESULTS: IL-1beta significantly stimulated MMP-9 production and mRNA expression. Trypsin converted latent MMP-2 and MMP-9 into their active forms of MMP-2 (66 kDa) and MMP-9 (82 kDa) within 24 hours. This conversion was significantly inhibited by 25(OH)D (100 nM) and 1,25(OH)2D (100 nM). The expression of MMP-9 mRNA was also significantly inhibited by 25(OH)D and 1,25(OH)2D. CONCLUSION: Vitamin D, 25(OH)D, and 1,25(OH)2D play a role in regulating human lung fibroblast functions in wound repair and tissue remodeling through not only inhibiting IL-1beta stimulated MMP-9 production and conversion to its active form but also inhibiting IL-1beta inhibition on TIMP-1 and TIMP-2 production.
Collagen
;
Emphysema
;
Enzyme-Linked Immunosorbent Assay
;
Fibroblasts*
;
Gelatin
;
Gels
;
Humans
;
Interleukin-1beta
;
Lung Diseases
;
Lung*
;
Matrix Metalloproteinase 9
;
Matrix Metalloproteinases
;
Polymerase Chain Reaction
;
Reverse Transcription
;
RNA, Messenger
;
Tissue Inhibitor of Metalloproteinase-1
;
Tissue Inhibitor of Metalloproteinase-2
;
Trypsin
;
Vitamin D*
;
Wounds and Injuries
4.Effects of Tetrandrine on the Nitric Oxide Production by Vascular Smooth Muscle Cells of the Rat.
Gi Su OH ; Na Young KIM ; Hyun Ock BAE ; Youn Chul KIM ; Jong Hyun HAN ; Young Myung KIM ; Byoung Sun AHN ; Hun Taeg CHUNG
Korean Journal of Immunology 2000;22(4):247-252
No abstract available.
Animals
;
Muscle, Smooth, Vascular*
;
Nitric Oxide*
;
Rats*
5.Effects of Rhodiola Sachalinensis on Nitric Oxide Synthesis by Macrophages, Hepatocytes, and Vascular Smooth Muscle Cells.
Hwa Kyung LEE ; Min Kyo SHIN ; Hyun Ock BAE ; Won Gil SEO ; Gi Su OH ; Byoung Sun AHN ; Hun Taeg CHUNG
Korean Journal of Immunology 2000;22(4):229-234
No abstract available.
Hepatocytes*
;
Macrophages*
;
Muscle, Smooth, Vascular*
;
Nitric Oxide*
;
Rhodiola*
6.Four Cases of Wernicke's Encephalopathy with Impaired Horizontal Vestibular Ocular Reflexes
Hyuk Su JANG ; Byoung Soo SHIN ; Man Wook SEO ; Sun Young OH
Journal of the Korean Balance Society 2017;16(2):57-63
Wernicke's encephalopathy (WE) is a neurological disorder induced by a dietary vitamin B1 (thiamine) deficiency which is characterized by encephalopathy, gait ataxia, and variant ocular motor dysfunction. In addition to these classical signs of WE, a loss of the horizontal vestibulo-ocular reflex (VOR) is being reported as the major underdiagnosed symptoms in WE. In this retrospective single center study, we report four cases of WE initially presented with impaired horizontal VOR in addition to the classical clinical presentations, and imaging and neurotological laboratory findings were described.
Ataxia
;
Brain Diseases
;
Dizziness
;
Gait Ataxia
;
Nervous System Diseases
;
Reflex
;
Reflex, Vestibulo-Ocular
;
Retrospective Studies
;
Thiamine
;
Wernicke Encephalopathy
7.Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer.
In Sil CHOI ; Do Youn OH ; Byoung Su KIM ; Keun Wook LEE ; Jee Hyun KIM ; Jong Seok LEE
Cancer Research and Treatment 2007;39(3):99-103
PURPOSE: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. MATERIALS AND METHODS: The study patients were chemotherapy-naive patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. RESULTS: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. CONCLUSION: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.
Aged*
;
Anemia
;
Drug Therapy*
;
Febrile Neutropenia
;
Fluorouracil*
;
Humans
;
Leucovorin*
;
Neutropenia
;
Peripheral Nervous System Diseases
;
Stomach Neoplasms*
8.A Case of Reversible Posterior Leukoencephalopathy Syndrome in a Patient with ABO Incompatible Kidney Transplantation.
Jong In KIM ; An Sook CHOI ; Su Jin KIM ; Byoung Hoon JI ; Joon Seok OH ; Young Ki SON ; Yong Hun SHIN ; Joong Kyung KIM
Korean Journal of Nephrology 2010;29(2):305-309
Reversible posterior leukoencepalopathy syndrome (RPLS) was noted by a reversible syndrome of headache, altered mental status, seizure, and visual loss associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies. We report a successful treatment of RPLS after secondary ABO incompatibility kidney transplantation with blood pressure control. A 41-year-old female whose primary kidney disease was chronic glomerulonephritis had graft failure developed after living donor kidney transplantation (1st kidney transplantation). She was admitted to our hospital for 2nd ABO incompatibility kidney transplantation. She had undergone 6 times of plasmapheresis and received additional two doses of rituximab (375 mg/m2) and intravenous immunoglobulin (0.5 g/kg) before kidney transplantation. She received basiliximab induction therapy, tacrolimus, steroid and mycophenolate mofetile after transplantation. The ABO antibody titer had been low (below 1:1) and evidences of rejection were not detected. Generalized tonic clonic type seizure, eyeball deviation, facial cyanotic change and loss of consciousness occurred at post operation 7th day. Several minutes later, she recovered her consciousness without disability and neurologic deficit. She did not represent attacks any more after we controlled blood pressure without withdrawal of immunosuppressants or dose reduction.
Adult
;
Antibodies, Monoclonal
;
Antibodies, Monoclonal, Murine-Derived
;
Blood Pressure
;
Consciousness
;
Female
;
Glomerulonephritis
;
Headache
;
Humans
;
Immunoglobulins
;
Immunosuppressive Agents
;
Kidney
;
Kidney Diseases
;
Kidney Transplantation
;
Leukoencephalopathies
;
Living Donors
;
Neurologic Manifestations
;
Plasmapheresis
;
Posterior Leukoencephalopathy Syndrome
;
Recombinant Fusion Proteins
;
Rejection (Psychology)
;
Seizures
;
Tacrolimus
;
Transplants
;
Unconsciousness
;
Rituximab
9.Rituximab and Plasmapheresis for Post-transplant Recurrence of FSGS.
Ju Yeon NAM ; An Sook CHOI ; Su Jin KIM ; Byoung Hoon JI ; Joon Suk OH ; Young Ki SON ; Yong Hun SIN ; Joong Kyung KIM ; Yong Jin KIM
Korean Journal of Nephrology 2010;29(2):292-295
Focal segmental glomerular sclerosis (FSGS) is known to recur in 20-40% of the renal allografts with graft loss in about half of these cases. We report a successful treatment of a recurrent FSGS after kidney transplantation with rituximab and plasmapheresis. An 16-year-old patient whose primary kidney disease was FSGS developed recurrence of proteinuria after living donor kidney transplantation despite preemptive plasmapheresis and one dose of rituximab (375 mg/m2). After kidney transplantation, nephrotic range proteinuria was detected. Kidney biopsy was done and showed recurrent FSGS. She undergone 11 times of plasmapheresis in the first 4 week post transplantation. In addition, she received additional one dose of rituximab (375 mg/m2) on day 14. Proteinuria was decreased below nephrotic range at 37 day. Ten months later, proteinuria was at 30 mg/day with excellent graft function. No significant adverse events related to rituximab or plasmapheresis were observed. Rituximab with plasmapheresis may be another option for recurrent FSGS after kidney transplantation.
Adolescent
;
Antibodies, Monoclonal, Murine-Derived
;
Biopsy
;
Glomerulosclerosis, Focal Segmental
;
Humans
;
Kidney
;
Kidney Diseases
;
Kidney Transplantation
;
Living Donors
;
Plasmapheresis
;
Proteinuria
;
Recurrence
;
Sclerosis
;
Transplantation, Homologous
;
Transplants
;
Rituximab
10.A case of fenoverine-induced rhabdomyolysis in diabetic nephropathy.
Kie Hoon KIM ; Mie Ryoung SIM ; Young Ha KYE ; Myeung Su LEE ; Byoung Hyun PARK ; Seon Ho AHN ; Seok Kyu OH ; Tae Hyun KIM ; Ju Hung SONG ; Chung Gu CHO
Korean Journal of Medicine 2002;62(4):465-468
Fenoverine is a non-atropine like spasmolytic drug that inhibits calcium channel currents in the smooth muscle. It has been occassionally reported that fenoverine can cause rhabdomyolysis under the certain conditions such as hepatic dysfunction, concomitant use of HMG-CoA reductase, mitochondrial myopathy, lipid storage myopathy or malignant hyperthermia. However, there is no report of fenoverine-induced rhabdomyolysis in type 2 diabetic nephropathy patient. So we describe here a case of fenoverine-induced rhabdomyolysis in type 2 diabetic patient. A 70-year-old man had both lower legs and shoulder pain for 5 days prior to hospital admission. He was a type 2 diabetic patient and had been managed for diabetic nephropathy. He had been consumed common doses of fenoverine for 20 days due to abdominal pain and diarrhea. Results of investigations showed evidence of rhabdomyolysis. Fenoverine therapy was stopped after admission and he was treated supportive care, his condition was recovered. In this case, renal function impairment may have been a predisposing factor for fenoverine-induced rhabdomyolysis. The incidence of muscular complications of fenoverine therapy could be reduced by avoidance of prescription of the drug in patients with diabetic nephropathy.
Abdominal Pain
;
Aged
;
Calcium Channels
;
Causality
;
Diabetic Nephropathies*
;
Diarrhea
;
Humans
;
Incidence
;
Leg
;
Malignant Hyperthermia
;
Mitochondrial Myopathies
;
Muscle, Smooth
;
Muscular Diseases
;
Oxidoreductases
;
Prescriptions
;
Rhabdomyolysis*
;
Shoulder Pain